- NASDAQ:INO sheds a further 2.95% on Friday as the stock continues to sink.
- Yet no sign that the FDA has loosened its stance on Inovio’s vaccine administrator: Cellectra 2000.
- Recent reports have indicated that although SARS-CoV-2 may be changing, existing vaccine candidates should still be effective.
NASDAQ:INO has continued to trend downwards as the stock dropped another 2.95% to close the week on Friday. From its high point on Tuesday, shares have plunged over 10% to its current price levels of $11.85 as Inovio approaches some of its lowest range of prices over the past six months. Shares have now dropped over 30% during the last month as investors grow weary of the future outlook of Inovio’s stalled COVID-19 vaccine candidate: INO-4800.
It is not only INO-4800 that the FDA had questions about, but the vaccine administrator as well. The Cellectra 2000 as it is named, issues a brief electrical pulse to open small skin pores where the vaccine enters and instructs cells to create the antigen. It remains unclear which part of the administrator the FDA had issues with. Shares have been beatdown ever since Inovio’s COVID-19 vaccine trials were paused and the longer that this goes on, it is likely that we will see the stock continue to struggle.
Inovio Pharmaceuticals stock
According to a report published by Australian scientists, the ongoing evolution of the COVID-19 virus, also known as SARS-CoV-2, should have little to no effect on existing vaccine candidates. The test the Australian scientists ran actually used INO-4800 on ferrets to test the vaccine candidate’s efficacy against two different strains of SARS-CoV-2. The results from both strains were that the ferrets had good responses to the vaccine in both cases. This can only be seen as good news for all of the horses in the Operation Warp Speed race that is currently underway, although Inovio continues to lag behind its rivals as time goes on.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD: The hunt for the 0.7000 hurdle
AUD/USD quickly left behind Wednesday’s strong pullback and rose markedly past the 0.6900 barrier on Thursday, boosted by news of fresh stimulus in China as well as renewed weakness in the US Dollar.
EUR/USD refocuses its attention to 1.1200 and above
Rising appetite for the risk-associated assets, the offered stance in the Greenback and Chinese stimulus all contributed to the resurgence of the upside momentum in EUR/USD, which managed to retest the 1.1190 zone on Thursday.
Gold holding at higher ground at around $2,670
Gold breaks to new high of $2,673 on Thursday. Falling interest rates globally, intensifying geopolitical conflicts and heightened Fed easing bets are the main factors.
Bitcoin displays bullish signals amid supportive macroeconomic developments and growing institutional demand
Bitcoin (BTC) trades slightly up, around $64,000 on Thursday, following a rejection from the upper consolidation level of $64,700 the previous day. BTC’s price has been consolidating between $62,000 and $64,700 for the past week.
RBA widely expected to keep key interest rate unchanged amid persisting price pressures
The Reserve Bank of Australia is likely to continue bucking the trend adopted by major central banks of the dovish policy pivot, opting to maintain the policy for the seventh consecutive meeting on Tuesday.
Five best Forex brokers in 2024
VERIFIED Choosing the best Forex broker in 2024 requires careful consideration of certain essential factors. With the wide array of options available, it is crucial to find a broker that aligns with your trading style, experience level, and financial goals.